A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
03
06
2024
accepted:
26
08
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
aheadofprint
Résumé
Mosunetuzumab, a T-cell engaging bispecific antibody targeting CD20xCD3, is approved for treating relapsed/refractory follicular lymphoma. This research supports the approved intravenous clinical dose regimen, summarizing the exposure-response relationships for clinical safety and efficacy. A population pharmacokinetic model and E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Roche
Informations de copyright
© 2024 Genentech, Inc. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Dreyling, M. et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann. Oncol. 32, 298–308 (2021).
U.S. Food and Drug Administration. Lunsumio highlights of prescribing information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf> Accessed May 15, 2024.
European Medicines Agency. Lunsumio summary of product characteristics. <https://www.ema.europa.eu/en/documents/product‐information/lunsumio‐epar‐product‐information_en.pdf>. [Accessed May 15, 2024].
Budde, L.E. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single‐arm, multicentre, phase 2 study. Lancet Oncol. 23, 1055–1065 (2022).
Jacobson, C.A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non‐Hodgkin lymphoma (ZUMA‐5): a single‐arm, multicentre, phase 2 trial. Lancet Oncol. 23, 91–103 (2022).
U.S. Food and Drug Administration. YESCARTA (axicabtagene ciloleucel). <https://www.fda.gov/vaccines‐blood‐biologics/cellular‐gene‐therapy‐products/yescarta‐axicabtagene‐ciloleucel> Accessed May 15, 2024.
Fowler, N.H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28, 325–332 (2022).
Morcos, P.N., Li, J., Hosseini, I. & Li, C.C. Quantitative clinical pharmacology of T‐cell engaging bispecifics: current perspectives and opportunities. Clin. Transl. Sci. 14, 75–85 (2021).
Sun, L.L. et al. Anti‐CD20/CD3 T cell‐dependent bispecific antibody for the treatment of B cell malignancies. Sci. Transl. Med. 7, 287ra70 (2015).
Gong, W.J. et al. Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B‐cell acute lymphoblastic leukemia patients receiving IL‐6 knocking down anti‐CD19 chimeric antigen receptor T‐cell therapy. Front. Immunol. 13, 922212 (2022).
Sheth, V.S. & Gauthier, J. Taming the beast: CRS and ICANS after CAR T‐cell therapy for ALL. Bone Marrow Transplant. 56, 552–566 (2021).
Hosseini, I. et al. Mitigating the risk of cytokine release syndrome in a phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst. Biol. Appl. 6, 28 (2020).
Li, J. et al. CD3 bispecific antibody‐induced cytokine release is dispensable for cytotoxic T cell activity. Sci. Transl. Med. 11, eaax8861 (2019).
Optimizing dosing in oncology drug development. Friends of Cancer Research Annual Meeting. <https://friendsofcancerresearch.org/wp‐content/uploads/Optimizing_Dosing_in_Oncology_Drug_Development.pdf> Accessed May 15, 2024.
Shah, M., Rahman, A., Theoret, M.R. & Pazdur, R. The drug‐dosing conundrum in oncology ‐ when less is more. N. Engl. J. Med. 385, 1445–1447 (2021).
Bender, B. et al. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma (R/R NHL). Clin. Transl. Sci. 17, e13825 (2024).
Ryman, J.T. & Meibohm, B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst. Pharmacol. 6, 576–588 (2017).
Budde, L.E. et al. Single‐agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B‐cell lymphomas: phase I dose‐escalation study. J. Clin. Oncol. 40, 481–491 (2022).
Lee, D.W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019).
Lee, D.W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).
Leclercq, G., Steinhoff, N., Haegel, H., De Marco, D., Bacac, M. & Klein, C. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Onco. Targets Ther. 11, 2083479 (2022).
Maude, S.L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
Nastoupil, L.J. CELESTIMO: a randomized phase III trial examining the efficacy and safety of mosunetuzumab in combination with lenalidomide versus rituximab in combination with lenalidomide in relapsed/refractory follicular lymphoma. Hematologist 19, 19 (2022).
Sehn, L.H. et al. Mosunetuzumab demonstrates durable responses in patients with relapsed/refractory lyphoma and ≥2 prior therapies: updated analysis of a pivotal phase II study. Haematol. Oncol. 41(suppl 2), 13–17 (2023).
Susilo, M.E. et al. Systems‐based digital twins to help characterize clinical dose‐response and propose predictive biomarkers in a phase I study of bispecific antibody, mosunetuzumab, in NHL. Clin. Transl. Sci. 16, 1134–1148 (2023).
Komanduri, K.V. et al. Development of a predictive model for cytokine release syndrome to inform risk stratification and CRS management following immunotherapy. Blood 138(suppl 1), 1459 (2021).
Chen, Y. & Xu, Y. Pharmacokinetics of bispecific antibody. Curr. Pharmacol. Rep. 3, 126–137 (2017).
An, G. Concept of pharmacologic target‐mediated drug disposition in large‐molecule and small‐molecule compounds. J. Clin. Pharmacol. 60, 149–163 (2020).
Wang, W., Wang, E.Q. & Balthasar, J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84, 548–558 (2008).
Gibiansky, E., Gibiansky, L., Carlile, D.J., Jamois, C., Buchheit, V. & Frey, N. Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non‐Hodgkin's lymphoma and exposure‐response in CLL. CPT Pharmacometrics Syst. Pharmacol. 3, e144 (2014).
Rozman, S., Grabnar, I., Novakovic, S., Mrhar, A. & Jezersek, N.B. Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome. Br. J. Clin. Pharmacol. 83, 1782–1790 (2017).
Budde, L.E. et al. Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B‐cell non‐Hodgkin lymphomas (B‐NHLs): updated results from a phase I/II study. Blood 140(suppl 1), 3753–3755 (2022).